Changes in Liver Function After Stereotactic Body Radiation Therapy Measured by PET/CT

University of Aarhus

Status: Completed

Conditions: Metastases; Hepatocellular Carcinoma; Cholangiocarcinoma; Stereotactic Body Radiotherapy

Treatments: Other: Measuring liver function by PET/CT

Study type: Observational

Funder types: Other

Identifiers

NCT01213758

AarhusLiverRadGal

Details and patient eligibility

About

Patients treated with stereotactic radiotherapy for liver tumors undergo PET/CT using the galactose analogue 18-F-deoxy-galactose (FDGal) before and after radiotherapy. This technique provides volumetric mapping of liver function and it allows quantisation of liver function. The method may be used for selection of patients for stereotactic radiotherapy of liver tumors, for determination of radiation induced liver dysfunction and may be included into the treatment planning process of stereotactic radiotherapy.

Enrollment: 14 patients

Sex: All

Ages: 18 to 85 years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• liver tumor
• referred for stereotactic radiation therapy
• age > 18 years

Exclusion criteria

• Impaired kidney function
• Pregnancy

Trial design

14 participants in 1 patient group

Liver tumors

Description:

Patients where stereotactic body radiation therapy is planned for primary or metastatic liver tumors.

Treatment:

Other: Measuring liver function by PET/CT